AbbVie (NYSE:ABBV) Trading 1.4% Higher – Time to Buy?

AbbVie Inc. (NYSE:ABBV) traded up 1.4% during trading on Tuesday . The company traded as high as $226.86 and last traded at $223.92. 5,643,268 shares changed hands during mid-day trading, a decline of 24% from the average session volume of 7,428,419 shares. The stock had previously closed at $220.77.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie completed a Phase 1 study for an on‑body injector for risankizumab, advancing a convenient delivery option for a key immunology product that could broaden use and adherence. On‑Body Injector Study Completion
• Positive Sentiment: Broker support: Berenberg raised its price target to $275 (Buy), citing momentum for Skyrizi and Rinvoq — a vote of confidence for AbbVie’s growth drivers. Berenberg Raises PT
• Positive Sentiment: AbbVie remains a high-yield Dividend King, which supports demand from income-focused investors and can help stabilize the stock during headline volatility. Dividend King Feature
• Neutral Sentiment: Options-market activity is drawing attention and could be amplifying intraday moves, but this is a flow/positioning signal rather than a fundamental change. Options Market Note
• Neutral Sentiment: Corporate giving/PR: The AbbVie Foundation opened applications for a health-equity accelerator — positive for ESG profile but unlikely to move near-term earnings. AbbVie Foundation Accelerator
• Negative Sentiment: Regulatory risk: CMS named several AbbVie branded drugs for the third cycle of the Medicare Drug Price Negotiation Program, including the first Part B‑reimbursed products — this increases the risk of mandated price cuts for Medicare patients and could pressure revenue for affected drugs. Medicare Price Negotiation
• Negative Sentiment: Analyst action: Citigroup trimmed its price target to $230 and moved to a Neutral rating, which reduces near-term upside expectations from that shop. Citigroup PT Cut
• Negative Sentiment: Competitive risk: Corcept reported robust Phase III ovarian cancer data for a therapy that could challenge Merck and AbbVie in certain oncology niches — a potential headwind if it advances to approval. Corcept Phase III Results

Wall Street Analyst Weigh In

ABBV has been the subject of several recent research reports. Scotiabank began coverage on shares of AbbVie in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 target price for the company. Piper Sandler reiterated an “overweight” rating and set a $289.00 price target (up previously from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Erste Group Bank cut shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Wall Street Zen lowered shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Finally, HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and lifted their target price for the stock from $225.00 to $265.00 in a report on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and an average target price of $247.84.

AbbVie Trading Up 1.4%

The stock has a fifty day moving average price of $225.14 and a 200-day moving average price of $218.00. The firm has a market capitalization of $395.75 billion, a price-to-earnings ratio of 169.64, a PEG ratio of 0.90 and a beta of 0.36.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. The firm had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period last year, the firm posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, equities analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be paid a $1.73 dividend. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date of this dividend is Friday, January 16th. AbbVie’s payout ratio is presently 524.24%.

Hedge Funds Weigh In On AbbVie

Institutional investors have recently modified their holdings of the stock. Norges Bank bought a new position in shares of AbbVie in the 2nd quarter worth $4,288,200,000. Wellington Management Group LLP raised its holdings in AbbVie by 457.4% during the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after buying an additional 8,646,424 shares during the period. Laurel Wealth Advisors LLC boosted its stake in AbbVie by 18,384.4% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock worth $1,059,141,000 after purchasing an additional 5,675,095 shares during the period. Vanguard Group Inc. boosted its position in shares of AbbVie by 1.9% during the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock worth $32,910,186,000 after buying an additional 3,380,842 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its holdings in shares of AbbVie by 169.3% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,722,893 shares of the company’s stock valued at $876,662,000 after purchasing an additional 2,969,202 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.